Last reviewed · How we verify
Tumor Associated Lymph node T cell — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Tumor Associated Lymph node T cell (Tumor Associated Lymph node T cell) — Guangzhou FineImmune Biotechnology Co., LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tumor Associated Lymph node T cell TARGET | Tumor Associated Lymph node T cell | Guangzhou FineImmune Biotechnology Co., LTD. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tumor Associated Lymph node T cell CI watch — RSS
- Tumor Associated Lymph node T cell CI watch — Atom
- Tumor Associated Lymph node T cell CI watch — JSON
- Tumor Associated Lymph node T cell alone — RSS
Cite this brief
Drug Landscape (2026). Tumor Associated Lymph node T cell — Competitive Intelligence Brief. https://druglandscape.com/ci/tumor-associated-lymph-node-t-cell. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab